CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $21.38M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 4.44: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.21BCNY776.78M · vs all stocks (USD)
Revenue (TTM)
143.26MCNY21.38M · vs all stocks (USD)
Profit Margin
-33.60%Beta
0.6350xvs all stocks
52-Week Change
56.19%vs all stocks
Market Capitalization
5.21BCNY776.78M · vs all stocks (USD)
Enterprise Value
5.54BCNY826.15M · vs all stocks (USD)
Price to Sales (TTM)
36.34xPrice to Book (MRQ)
7.89xEnterprise to Revenue
38.65xEnterprise to EBITDA
-119.52xGross Margin
13.08%Profit Margin
-33.60%Operating Margin
-27.50%Return on Assets (TTM)
-4.43%Return on Equity (TTM)
-9.93%Revenue (TTM)
143.26MCNY21.38M · vs all stocks (USD)
Revenue per Share (TTM)
1.80CNYUpdated Sep 19, 2026Quarterly Revenue Growth
10.70%Gross Profit (TTM)
8.98MCNY1.34M · vs all stocks (USD)
EBITDA (TTM)
-46.32MCNY-6.91M · vs all stocks (USD)
Net Income (TTM)
-48.14MCNY-7.18M · vs all stocks (USD)
Operating Cash Flow (TTM)
-63.63MCNY-9.50M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-106.91MCNY-15.95M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
49.03MCNYFY2025 · Dec 31, 2025Revenue
154.18MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
141.58MCNYFY2025 · Dec 31, 2025Gross Profit
12.60MCNYFY2025 · Dec 31, 2025Operating Income
-94.52MCNY-14.10M · vs all stocks (USD)
Pre-tax Income
-131.36MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.04MCNYFY2025 · Dec 31, 2025Net Income
-132.40MCNYFY2025 · Dec 31, 2025EBIT
-113.42MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-43.21MCNYFY2025 · Dec 31, 2025Research & Development
32.41MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
28.67MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.51MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.23MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
17.94MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.29CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.29CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
79.20MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
79.20MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-132.40MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
30.23MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-142.02MCNYFY2025 · Dec 31, 2025Free Cash Flow
-243.06MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
85.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-132.40MCNYFY2025 · Dec 31, 2025Other Non-cash Items
18.26MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
16.29MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-44.16MCNYFY2025 · Dec 31, 2025Capital Expenditures
-101.04MCNYFY2025 · Dec 31, 2025Net Acquisitions
8.80MCNYFY2025 · Dec 31, 2025Purchase of Investments
-812.99MCNYFY2025 · Dec 31, 2025Sale of Investments
925.26MCNYFY2025 · Dec 31, 2025Other Investing Activity
152.55MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
172.58MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
127.70MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-183.91MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.79MCNYFY2025 · Dec 31, 2025Other Financing Charges
-86.59MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-151.59MCNYFY2025 · Dec 31, 2025Shares Outstanding
80.00MSharesUpdated Sep 19, 2026Float Shares
70.02MSharesUpdated Sep 19, 2026% Held by Insiders
69.43%vs all stocks
% Held by Institutions
0.71%vs all stocks
Total Cash (MRQ)
64.92MCNY9.69M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.8120CNYUpdated Sep 19, 2026Total Debt (MRQ)
355.39MCNY53.03M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5078xCurrent Ratio (MRQ)
0.6610xBook Value per Share (MRQ)
8.24CNYUpdated Sep 19, 2026Total Assets
1.28BCNY191.48M · vs all stocks (USD)
Total Current Assets
329.06MCNYFY2025 · Dec 31, 2025Total Liabilities
659.67MCNYFY2025 · Dec 31, 2025Total Non-current Assets
954.15MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
217.54MCNYFY2025 · Dec 31, 2025Total Current Liabilities
442.14MCNYFY2025 · Dec 31, 2025Cash
85.28MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.17KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
85.28MCNYFY2025 · Dec 31, 2025Other Short-term Investments
20.04MCNYFY2025 · Dec 31, 2025Accounts Receivable
80.10MCNYFY2025 · Dec 31, 2025Inventory
83.54MCNYFY2025 · Dec 31, 2025Accounts Payable
77.29MCNYFY2025 · Dec 31, 2025Short-term Debt
178.12MCNYFY2025 · Dec 31, 2025Other Current Liabilities
7.65MCNYFY2025 · Dec 31, 2025Long-term Debt
92.23MCNYFY2025 · Dec 31, 2025Common Stock (Book)
80.00MCNYFY2025 · Dec 31, 2025Retained Earnings
-12.79MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
623.54MCNY93.04M · vs all stocks (USD)
Treasury Stock
20.99MCNYFY2025 · Dec 31, 202552-Week Low
39.10CNYUpdated Sep 19, 202652-Week High
98.29CNYUpdated Sep 19, 202652-Week Change
56.19%vs all stocks
Beta
0.6350xvs all stocks
50-Day MA
55.87CNYUpdated Sep 19, 2026200-Day MA
65.44CNYUpdated Sep 19, 2026Avg 10-Day Volume
992.35KSharesUpdated Sep 19, 2026Avg 30-Day Volume
1.21MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.6100CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.44: safe zoneNotable
Altman Z-Score: 4.44
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $21.38M, lower than 95% of all stocks globallySignificant
Revenue (USD): 21,377,152.149Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Immix Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule